Locations:
Search
What is the role of autologous stem cell transplantation in multiple myeloma given the availability of potent new chemotherapeutic agents now used in combination regimens, what is optimal timing for transplantation and which patients might benefit?
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this “top takeaway” feature, Navneet Majhail, MD, MS, Director of Cleveland Clinic’s Blood & Marrow Transplant Program, and Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, review findings presented at ASH, share their thoughts and discuss ongoing research.
Photo Credit ©Russell Lee
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust